Results 251 to 260 of about 114,065 (338)

First‐Line Treatment of IGHV‐Unmutated Chronic Lymphocytic Leukemia: A Network Meta‐Analysis of Targeted and Chemoimmunotherapy Regimens

European Journal of Haematology, EarlyView.
ABSTRACT Immunoglobulin heavy chain variable region‐unmutated (IGHV‐U) chronic lymphocytic leukemia (CLL) represents a biologically aggressive subgroup with limited responsiveness to chemoimmunotherapy (CIT). To clarify the comparative effectiveness of available frontline options, we conducted a comprehensive Bayesian network meta‐analysis of ...
Santino Caserta, Enrica Antonia Martino, Danilo Lofaro, Ernesto Vigna, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Fortunato Morabito, Valter Gattei, Massimo Gentile   +13 more
wiley   +1 more source

Humoral and functional SARS-CoV-2-specific T-cell responses elicited in chronic lymphocytic leukaemia patients with GEO-CM04S1 a synthetic MVA-vectored COVID-19 vaccine. [PDF]

Br J Haematol
Ortega-Francisco S, Prudente de Aquino MT, La Rosa C, Chiuppesi F, Gutierrez MA, Miller J, Li J, Mack-Onyeike J, Zhou Y, Zhou Q, Kaltcheva T, Patterson A, Dempsey S, Thomas S, Tiemann K, Yang D, Rida W, Wussow F, McKee K, Taplitz R, Raiden E, Siddiqi T, Rosen S, Diamond DJ, Danilov A.   +24 more
europepmc   +1 more source

Bone Marrow Pathology in Cold Agglutinin‐Mediated Autoimmune Hemolytic Anemia: A Study of 56 Cases

European Journal of Haematology, EarlyView.
ABSTRACT Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia (AIHA). CAD occurs in the context of a small clonal B‐cell lymphoproliferation restricted to blood and/or bone marrow (BM), without overt or extramedullary lymphoma. The WHO‐HAEM5 introduced a description of the CAD‐associated lymphoproliferative disorder (CAD‐LPD) in ...
Anne‐Marie L. Becking, Sophie J. Bernelot Moens, Marie José Kersten, Femke V. M. Mulder, Steven T. Pals, Lianne Koens, Josephine M. I. Vos   +6 more
wiley   +1 more source

Elucidating novel immune profiles for predicting infection in high-risk cohorts: a pilot study in patients with relapsed and refractory chronic lymphocytic leukaemia. [PDF]

Clin Transl Immunology
Williams LJ, Li-Wai-Suen CS, Garnham AL, Bader SM, Tam CS, Whitechurch A, Slavin MA, Doerflinger M, Teh BW.   +8 more
europepmc   +1 more source

From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management

European Journal of Haematology, EarlyView.
ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Maria Eugenia Alvaro, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Mamdouh Skafi, Valter Gattei, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source

Rare germline ATM variants predispose to secondary cancer in chronic lymphocytic leukaemia patients. [PDF]

Cancer Commun (Lond)
Petrackova A, Manakova J, Nesnadna R, Kubova Z, Papajik T, Kriegova E.   +5 more
europepmc   +1 more source

Regional Standardization of CLL Management: Results of a Delphi Consensus Process

European Journal of Haematology, EarlyView.
ABSTRACT The therapeutic landscape of chronic lymphocytic leukemia (CLL) has been profoundly transformed by the introduction of Bruton tyrosine kinase and BCL‐2 inhibitors. Despite improved survival outcomes, treatment selection remains complex, particularly in older patients with comorbidities, frailty, and increased infectious vulnerability.
Enrica Antonia Martino, Annalisa Chiarenza, Salvatrice Mancuso, Marco Rossi, Caterina Stelitano, Ignazio Abbene, Sergio Cabibbo, Daniele Caracciolo, Emilia Cotzia, Amalia Figuera, Antonino Greco, Vanessa Innao, Luciano Levato, Carla Marino, Giuseppe Mineo, Laura Nocilli, Giuseppa Penna, Marika Porrazzo, Giorgio Tona, Ernesto Vigna, Fortunato Morabito, Daniela D'Angela, Massimo Gentile   +22 more
wiley   +1 more source

Real-world safety and effectiveness of alemtuzumab for relapsed or refractory chronic lymphocytic leukaemia: results from postmarketing surveillance in Japan. [PDF]

Jpn J Clin Oncol
Sasakura Y, Hatanaka M, Ishizawa K.
europepmc   +1 more source

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies

European Journal of Haematology, EarlyView.
ABSTRACT Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials.
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +14 more
wiley   +1 more source

Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype. [PDF]

Br J Haematol
Serafin A, Ruocco V, Cellini A, Angotzi F, Bonaldi L, Trentin L, Visentin A.   +6 more
europepmc   +1 more source